<code id='E2F2961BD2'></code><style id='E2F2961BD2'></style>
      • <acronym id='E2F2961BD2'></acronym>
      <center id='E2F2961BD2'><center id='E2F2961BD2'><tfoot id='E2F2961BD2'></tfoot></center><abbr id='E2F2961BD2'><dir id='E2F2961BD2'><tfoot id='E2F2961BD2'></tfoot><noframes id='E2F2961BD2'>
      • <optgroup id='E2F2961BD2'><strike id='E2F2961BD2'><sup id='E2F2961BD2'></sup></strike><code id='E2F2961BD2'></code></optgroup>
        5. <b id='E2F2961BD2'><label id='E2F2961BD2'><select id='E2F2961BD2'><dt id='E2F2961BD2'><span id='E2F2961BD2'></span></dt></select></label></b><u id='E2F2961BD2'></u>
          <i id='E2F2961BD2'><strike id='E2F2961BD2'><tt id='E2F2961BD2'><pre id='E2F2961BD2'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / explore      
           
     
           
      
          explore 
           
      
           
      
           
       2025-10-06 16:12:18 
   
      
           
      
           
                        
          explore  
          
                                   
                 
                                      author：explore   
                                        
                                      
                                      Page View：5
                                  
                                    
          
                                   
          Alexis Borisy
          Venture capitalist Alexis Borisy																									Vanessa Leroy for STAT
          EQRx is done, sold for its cash.
          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
          advertisement
          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!					
          GET STARTED													Log In											
                      
                              
          
                                 Previous article：

                                
                                          The biotech scorecard for Q4: 16 stock
                                
                            
          Next article：  
                                      
                                          Hepatitis C has a cure — but many Americans still lack access to it
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles